Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2003
10/23/2003US20030199463 For therapy of cardiovascular disease, fibrotic disease
10/23/2003US20030199425 Administering a drug that inhibits proliferation and cell migration, and a biocompatible protein; reduced toxicity.
10/23/2003US20030199103 Novel amino acid sequences for human epidermal growth factor-like polypeptides
10/23/2003US20030199067 Growth arrest homeobox gene
10/23/2003US20030199043 Therapeutic proteins (including polypeptide, antibody, peptide or fragment or variants)fused to albumin or fragment or variant linked by a linker peptide; nonglycosylated
10/23/2003US20030198975 Proteins associated with cell growth, differentiation, and death
10/23/2003US20030198953 For diagnosis, treatment, and prevention of related disorders
10/23/2003US20030198949 Viral polypeptides that regulate or modulate apoptosis
10/23/2003US20030198690 Administering zinc using stent; antiproliferative agent
10/23/2003US20030198666 Side effect reduction; using mixture of insulin and adjuvant
10/23/2003US20030198620 Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
10/23/2003US20030198619 Mixture containing permeability intensifier; in situ gelation using nonionic surfactant
10/23/2003CA2482937A1 A novel crystal of anhydride of a quinoxalinedione derivative
10/23/2003CA2482904A1 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
10/23/2003CA2482903A1 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
10/23/2003CA2482718A1 Derivatives of the il-2 receptor gamma chain, their production and use
10/23/2003CA2482713A1 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
10/23/2003CA2482703A1 Medicinal composition for improving angiotension-regulating function of blood vessel endothelium
10/23/2003CA2482387A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use
10/23/2003CA2482382A1 Pyrazole compounds as anti-inflammatory and analgesic agents
10/23/2003CA2482236A1 Composition for preventing atherosclerosis
10/23/2003CA2482216A1 Patch and process for producing the same
10/23/2003CA2481747A1 Recombinant anti-interleukin-9 antibodies
10/23/2003CA2481669A1 Preparation and use of a stable formulation of allosteric effector compounds
10/23/2003CA2481595A1 Solid dispersion composition
10/23/2003CA2481532A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003CA2481519A1 Electrocardiographic aspects of chf treatment
10/23/2003CA2481387A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003CA2481385A1 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
10/23/2003CA2481384A1 Aqueous dispersible steryl ester compositions
10/23/2003CA2481313A1 Bicyclic amides
10/23/2003CA2481282A1 Protein a compositions and methods of use
10/23/2003CA2481240A1 Aminocarbonyl substituted pyridines, pyridazines, pyrimidines, pyrazines and triazines having antiangiogenic activity
10/23/2003CA2480882A1 Low-dose potassium supplementation for the prevention and treatment of hypertension
10/23/2003CA2480860A1 Tri-substituted heteroaryls and methods of making and using the same
10/23/2003CA2480856A1 Substituted aryl amides
10/23/2003CA2480832A1 Nitric oxide donors, compositions and methods of use
10/23/2003CA2480763A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
10/23/2003CA2480758A1 Tyrosine kinase inhibitors
10/23/2003CA2480754A1 Tyrosine kinase inhibitors
10/23/2003CA2480512A1 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
10/23/2003CA2480415A1 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
10/23/2003CA2480410A1 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
10/23/2003CA2480217A1 G-type peptides to ameliorate atherosclerosis
10/23/2003CA2479996A1 Compositions for delivering enyzmes involved in acid metabolism using recombinant adeno-associated virus virons (raav virons), and method and use for treating amino acid metabolicdisorders using such raav virons
10/23/2003CA2478392A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
10/23/2003CA2477692A1 Cyanamides useful as reversible inhibitors of cysteine proteases
10/22/2003EP1355158A1 Method for diagnosing inflammatory and infectious diseases by detecting the phosphoprotein LASP-1 as inflammation marker
10/22/2003EP1354953A1 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/22/2003EP1354888A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines
10/22/2003EP1354884A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
10/22/2003EP1354882A1 Dipeptidyl peptidase iv inhibitor
10/22/2003EP1354878A2 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
10/22/2003EP1354877A1 Hetero-tricyclic compounds having substituted amino groups
10/22/2003EP1354873A1 Salt of perindopril and pharmaceutical compositions containing it
10/22/2003EP1354871A1 Biphenyl derivatives
10/22/2003EP1354868A1 Perfluoronated cycle-containing tertiary amines used as a basis for gas-conveying emulsions and device for the production thereof
10/22/2003EP1354604A1 Combinations for cardiovascular indications
10/22/2003EP1354603A1 Concomitant drugs
10/22/2003EP1354598A2 Therapeutic uses of BR43X2 soluble receptors
10/22/2003EP1354597A2 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
10/22/2003EP1354589A1 Angiogenesis inhibitors
10/22/2003EP1354047A2 Methods for screening compounds that modulate lipid metabolism
10/22/2003EP1354046A2 A member of the lysyl oxidase gene family
10/22/2003EP1353954A2 Anticoagulants and their uses
10/22/2003EP1353946A2 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
10/22/2003EP1353927A2 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/22/2003EP1353926A1 Mikanolide derivatives, their preparation and therapeutic uses
10/22/2003EP1353918A1 Morpholine derivatives as antagonists of orexin receptors
10/22/2003EP1353916A2 Pyrazole compounds useful as protein kinase inhibitors
10/22/2003EP1353914A2 Therapeutic chromone compounds
10/22/2003EP1353913A2 Therapeutic heterocyclic compounds
10/22/2003EP1353912A1 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
10/22/2003EP1353909A2 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
10/22/2003EP1353907A2 Phosphodiesterase 4 inhibitors
10/22/2003EP1353906A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
10/22/2003EP1353905A2 Piperidine/piperazine-type inhibitors of p38 kinase
10/22/2003EP1353904A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/22/2003EP1353903A2 Thiol-based naaladase inhibitors
10/22/2003EP1353898A2 Compounds to treat alzheimer's disease
10/22/2003EP1353727A2 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
10/22/2003EP1353696A2 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
10/22/2003EP1353695A2 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
10/22/2003EP1353694A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
10/22/2003EP1353692A2 Methods and compositions for treatment of ocular neovascularization and neural injury
10/22/2003EP1353684A2 Use of inhibitors of dipeptidypeptidase iv (ec 3.3.14.5) and aminopeptidase n (ec 3.4.11.2) for the treatment of neurodegeneration induced by ischaemia
10/22/2003EP1353679A2 Compositions, methods and apparatuses for singlet oxygen delivery
10/22/2003EP1353675A2 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/22/2003EP1353672A2 Synthesis of 3-amino-thalidomide and its enantiomers
10/22/2003EP1353662A2 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
10/22/2003EP1353658A1 Regulation of organic nitrate tolerance
10/22/2003EP1353569A2 Preparation for improved dietary utilisation
10/22/2003EP1194441B1 A2a receptor agonists
10/22/2003EP1192122B1 Benzene derivatives, preparation method and pharmaceutical compositions containing same
10/22/2003EP1183236B1 Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives
10/22/2003EP1150661B1 Topical sprays comprising a film forming composition
10/22/2003EP1144386B1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
10/22/2003EP1140745B1 Colchinol derivatives as vascular damaging agents
10/22/2003EP1131073B1 Use of staurosporine derivatives for treating ocular neovascular diseases
10/22/2003EP1056754B1 Phosphate derivatives of diaryl 1,3,4-oxadiazolone
1 ... 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 ... 1595